Saturday, July 19, 2025 10:54:38 AM
"If DCVax-L is approved after July 23, it benefits from this framework directly. If approved before, any later switch to Flaskworks would be considered a major variation, requiring extensive revalidation."
I thought flaskworks was allready approved and part of the submission.
I also thought variations had to be submitted during approval process.
Why would a better automated system delay approval of a treatment? Better systems are developed all the time and stand on their own for validation.
"What are the implications of SI 2025 No. 87?
The implications of SI 2025 No. 87, which takes effect at the UK’s MHRA on July 23, 2025, are quite significant—especially for cutting-edge therapies like DCVax-L from Northwest Biotherapeutics."
This is why I hate AI. What will tomorrow be like? Answer- tomorrow will have weather and last 24 hrs.
If approval happens this week or the next, I'll be happy as a clam. But I don't believe the delay of over 1 1/2 years was due to waiting for this new regulation. It seems like investors are trying to find a timeline on which to look forward to and are creating narratives to justify this timeline. JMO
I thought flaskworks was allready approved and part of the submission.
I also thought variations had to be submitted during approval process.
Why would a better automated system delay approval of a treatment? Better systems are developed all the time and stand on their own for validation.
"What are the implications of SI 2025 No. 87?
The implications of SI 2025 No. 87, which takes effect at the UK’s MHRA on July 23, 2025, are quite significant—especially for cutting-edge therapies like DCVax-L from Northwest Biotherapeutics."
This is why I hate AI. What will tomorrow be like? Answer- tomorrow will have weather and last 24 hrs.
If approval happens this week or the next, I'll be happy as a clam. But I don't believe the delay of over 1 1/2 years was due to waiting for this new regulation. It seems like investors are trying to find a timeline on which to look forward to and are creating narratives to justify this timeline. JMO
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
